Note: Specific details of MIRD-226 are subject to change based on the hosting agency and year of execution. This article synthesizes public training objectives, equipment standards, and after-action themes common to the MIRD series as of 2026.

The development of MIRD-226 dates back to the early 2000s, when researchers began exploring the use of radiolabeled somatostatin analogues for the treatment of NETs. The first generation of these radiopharmaceuticals, such as In-111-DOTATOC, showed promising results in diagnosing and treating NETs. However, they had limitations, including a short half-life and limited availability.

Biokinetic Modeling

The MIRD-226 is currently being researched and developed for various medical applications. Several studies have been conducted to evaluate its safety and efficacy in cancer therapy and imaging. While the MIRD-226 shows great promise, there are still challenges to be addressed, such as:

Special Considerations